Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update
Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 millionCash resources and cash ...
Endocrinology Advisor16d
FDA Approves Ctexli for Cerebrotendinous Xanthomatosis
The Food and Drug Administration has approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis in adults.
Medical Dialogues14d
Study identifies persistent lymphopenia as Key Predictor of In-Hospital Mortality in Immunocompromised CKD Patients
Researchers have found in new research that persistent lymphopenia is the most significant predictor of in-hospital mortality ...
News Medical3d
One beam bilirubinometer from Ginevri
The One Beam allows for a rapid photo-metric analysis of the bilirubin total in the serum (totals of the conjugated and non-conjugated) using a capillary tube as an optical cell. The bilirubin ...
Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, ...
Le Lézard10d
Shorla Oncology Announces Expansion of U.S. Commercial Footprint with Launch of Dedicated Sales Force and Market Access Teams
Hepatic Impairment: Reduce the dose by 25% for patients with severe hepatic impairment. Patients with mild hepatic impairment (total bilirubin ? upper limit of normal [ULN] and aspartate ...
The Manila Times10d
Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update
On July 30, 2024, Chemomab announced the closing of a private placement that resulted in gross proceeds of approximately $10 million to the company. Existing investors such as OrbiMed and new ...
Biohaven reports ‘positive’ data from study of BHV-1300
Biohaven (BHVN) highlighted the success of BHV-1300, its potential first-in-class IgG selective degrader, in achieving rapid and deep ...
Septerna, Inc. (SEPN): Among The Stocks With At Least $30 Million In Insider Spending Recently
We recently compiled a list of the 10 Stocks With At Least $30 Million In Insider Spending Recently. In this article, we are ...
Strong Immunoglobulin Reduction Data Positions Biohaven's BHV-1300 As Potential Autoimmune Therapy
Biohaven's BHV-1300 reduced IgG levels by up to 84% in a Phase 1 trial for autoimmune disease, with rapid and sustained effects and a favorable safety profile.